Clinical trials: Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Japanese Patients With ALS
Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis
To evaluate the pharmacokinetics of single doses of edaravone oral suspension in Patients with Amyotrophic Lateral Sclerosis
- Trial name
- NCT04176224
- Testing
- MT-1186
- Where
- Japan
- Volunteers
- 9 people
- Sponsor
- Shionogi
Amyotrophic Lateral Sclerosis, Psychological Stress
Psychological Therapy for Patients With ALS
Amyotrophic lateral sclerosis (ALS) is a disease that is inevitably fatal. To be diagnosed with a terminal illness such as ALS deeply affects one's personal existence and goes along with significant changes regarding the…
- Trial name
- NCT03975608
- Testing
- Adaptation of "CALM"
- Where
- Germany
- Volunteers
- 5 people
- Sponsor
- University of Leipzig
Amyotrophic Lateral Sclerosis
G-CSF Treatment for Amyotrophic Lateral Sclerosis: A RCT Study Assessing Clinical Response
This study will examine the effectiveness of G-CSF in treating patients with amyotrophic lateral sclerosis (ALS) - a fatal neurological degenerative disease that causes adult-onset, progressive motor neurons loss in the spinal…
- Trial name
- NCT00397423
- Testing
- Granulocyte Colony Stimulating Factor, NS
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University
Amyotrophic Lateral Sclerosis
Evaluate the Safety of Neuronata-R® Inj. Suspended With HypoTHermosol® FRS (HTS-FRS) in Patients With ALS
This clinical trial is a single-center, open-label, and phase I clinical trial to Evaluate the Safety of Neuronata-R® Inj. suspended with HypoTHermosol® FRS (HTS-FRS) in Patients with Amyotrophic Lateral Sclerosis.
- Trial name
- NCT06676423
- Testing
- Lenzumestrocel, Riluzole
- Where
- South Korea
- Volunteers
- 8 people
- Sponsor
- Corestemchemon, Inc.
Amyotrophic Lateral Sclerosis, Fasciculation
Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS
The FLX-787-107 study will determine how well FLX-787-ODT works to reduce fasciculations in patients with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT03334786
- Testing
- FLX-787-ODT
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Flex Pharma, Inc.
Amyotrophic Lateral Sclerosis
Tofacitinib in Patients With Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease, of which motor-neuron's degeneration may be associated with neuroinflammation.
- Trial name
- TALENT (NCT06689982)
- Testing
- Tofacitinib tablets
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Beijing Tiantan Hospital
Amyotrophic Lateral Sclerosis
Exploring Nasal Drop Therapy With Small Extracellular Vesicles for ALS
This is a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial. The goal of this clinical trial is to evaluate the safety and preliminary efficacy of nasal drop exosomes derived from human umbilical…
- Trial name
- de-ALS (NCT06598202)
- Testing
- exosomes derived from human umbilical cord blood mesenchymal stem cells for nasal drop
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Xuanwu Hospital, Beijing
Amyotrophic Lateral Sclerosis (ALS)
Circulating Biomarker for Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS) is a rare disease with a worldwide incidence of 2-3 cases per 100,000 individuals/year and it is characterized by progressive neurodegeneration of motor neurons.
- Trial name
- NCT03088839
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Neuromed IRCCS
Amyotrophic Lateral Sclerosis
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis
The primary objective of this study is to evaluate the safety and tolerability of BIIB078 in adults with C9ORF72-Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT03626012
- Testing
- BIIB078
- Where
- 21 sites in United States, Canada and 4 more
- Volunteers
- 106 people
- Sponsor
- Biogen
Alzheimer Disease, FTD
Omics Sciences for the Identification of Pathogenetic Mechanisms and Biomarkers in Neurodegenerative Diseases
The study aims to use 'omics' sciences, employing the most advanced technologies currently available, in order to identify pathogenic genomic variants, proteins and/or altered molecular pathways in neurodegenerative diseases and…
- Conditions
- Alzheimer Disease, FTD, Young-onset Dementia, MCI
- Trial name
- NeurOmics (NCT07235111)
- Where
- Italy
- Volunteers
- 1,200 people
- Sponsor
- Ospedale Policlinico San Martino
Amyotrophic Lateral Sclerosis
A Study Evaluating the Safety and Tolerability of QRL-201 in ALS
The primary objective of this study is to determine the safety and tolerability of multiple doses of QRL-201 in people living with ALS
- Trial name
- NCT05633459
- Testing
- Multiple ascending doses of QRL-201, QRL-201
- Where
- 15 sites in Belgium, Canada and 4 more
- Volunteers
- 69 people
- Sponsor
- QurAlis Corporation
Amyotrophic Lateral Sclerosis, ALS
RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial
Triumeq is an approved medicine for HIV. The effectiveness of Triumeq in Amyotrophic Lateral Sclerosis (ALS) is being investigated in the Lighthouse II trial.
- Trial name
- Lighthouse III (NCT06658977)
- Testing
- Abacavir 600mg, Lamivudine 300mg and Dolutegravir 50mg (Triumeq)
- Where
- 7 sites in Australia
- Volunteers
- 12 people
- Sponsor
- Macquarie University, Australia
Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) Gulf War Study
Recently, concern has arisen regarding a possible elevated occurrence of ALS among veterans who served in the Persian Gulf during Operations Desert Shield (August 2, 1990 - January 15, 1991), Desert Storm (January 16, 1991 …
- Trial name
- NCT00007722
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- US Department of Veterans Affairs
Amyotrophic Lateral Sclerosis
Anticipated Patient and Caregiver Burden
Amyotrophic lateral sclerosis (ALS) is a degenerative neurological disease that causes progressive motor disability and is life threatening within a few years.
- Trial name
- FARP (NCT05632757)
- Testing
- Psychological assessments
- Where
- France
- Volunteers
- 126 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Complete or Incomplete Paraplegia/quadriplegia, Spinal Cord Injury
Research on Wireless Brain Implant System for General Control of External Devices
The clinical trial aims to evaluate the safety and efficacy of the minimally invasive, wireless brain-machine interface system (WRS) in enabling general brain control of external devices, such as a cursor and other assistive…
- Conditions
- Complete or Incomplete Paraplegia/quadriplegia, Spinal Cord Injury, Brainstem Stroke, Amyotrophic Lateral Sclerosis
- Trial name
- RISE (NCT06829212)
- Testing
- WRS
- Where
- China
- Volunteers
- 4 people
- Sponsor
- Shanghai StairMed Technology Co., Ltd.
Amyotrophic Lateral Sclerosis, Neurodegenerative Disease
Amyotrophic Lateral Sclerosis (ALS) Tissue Donation Program
Despite significant progress in the identification of mechanisms involved in motor neuron degeneration in Amyotrophic Lateral Sclerosis (ALS) and other motor system diseases, the actual pathogenesis and cause of these diseases…
- Conditions
- Amyotrophic Lateral Sclerosis, Neurodegenerative Disease, Motor Neuron Disease
- Trial name
- NCT00716131
- Where
- United States
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- Drexel University College of Medicine
Amyotrophic Lateral Sclerosis (ALS)
Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis
The purpose of this study is to determine whether nine months of administration of creatine monohydrate results in an increase in muscle strength in patients with amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT00069186
- Testing
- Creatine Monohydrate
- Where
- 8 sites in United States
- Volunteers
- 107 people
- Sponsor
- The Avicena Group
Amyotrophic Lateral Sclerosis, ALS-Frontotemporal Dementia
Clinical Procedures to Support Research in ALS
The purpose of the Clinical Procedures To Support Research (CAPTURE) study is to utilize information collected in the medical record to learn more about a disease called amyotrophic lateral sclerosis (ALS) and related disorders.
- Conditions
- Amyotrophic Lateral Sclerosis, ALS-Frontotemporal Dementia, Primary Lateral Sclerosis, Progressive Muscular Atrophy
- Trial name
- CAPTURE-ALS (NCT03489278)
- Where
- 11 sites in United States
- Volunteers
- 1,200 people
- Sponsor
- University of Miami
ALS, Amyotrophic Lateral Sclerosis
Effect of MD1003 in Amyotrophic Lateral Sclerosis
This is a 6-month double blind randomized 2:1 placebo-controlled study with two arms (placebo, biotin 300 mg/day). The study will be followed by a 6-month extension phase during which all patients will receive biotin 300 mg/day.
- Conditions
- ALS, Amyotrophic Lateral Sclerosis, Motor Neuron Disease
- Trial name
- MD1003-ALS (NCT03114215)
- Testing
- MD1003
- Where
- France
- Volunteers
- 30 people
- Sponsor
- MedDay Pharmaceuticals SA
Primary Lateral Sclerosis
Screening and Natural History: Primary Lateral Sclerosis and Related Disorders
Objective: The objectives of this protocol are: to develop and maintain a repository of clinically characterized patients with primary lateral sclerosis for future research protocols, to characterize the natural history of…
- Trial name
- NCT00015444
- Where
- United States
- Volunteers
- 189 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)